T: +44 (0)1623 751 500
E: info@advancissurgical.com

Clinical benefits

Hemosep offers a significant number of clinical benefits when utilised for intraoperative cell salvage:
Hemosep-blood
  • Patient receives their own blood back
  • Decreased need for blood transfusion
  • Decreased blood loss
  • Maintenance of platelet population
  • Reduction in inflammatory molecules
  • Reduced risk of contamination or reaction
  • Reduction in donor demand
  • Improved patient recovery
  • Reduction in post-operative complications
Cardiac Surgery

Cardiac Application

Haemoconcentration has been conducted for many years, either during an operative procedure or, more commonly, on the residual blood left in the CPB system at its termination, to concentrate the blood cells prior to re-administration to the patient.

The Hemosep cell salvage system can be utilised to concentrate the residual blood following the termination of the CPB system. This approach reduces the need for donor blood and associated products, therefore reducing the donor blood risks.

To collect the blood left in the heart lung machine, the Hemosep Cell Concentrator Bag can simply be connected to the tubing below the reservoir for gravity fill applications.

Intraoperative application

Additional developments to Hemosep technology have resulted in the option to utilise the system for intraoperative cell salvage. The use of the Hemosep intraoperative system presents a wealth of application possibilities. With the inclusion of the intraoperative suction tool and blood reservoir the device can be used during any blood loss procedure. Using the suction tool, blood is aspirated directly from the surgical site into the intraoperative blood reservoir. 

Using a unique method for cell concentration, the system is able to effectively produce a high quality blood product in order to aid the patient recovery time and dramatically reduce the need for donor blood and associated products.

The intraoperative option is available to give health care professionals flexibility of use by utilising the suction capabilities of the device and assessing the appropriate direction to either filter the blood or disregard and take other action. The Hemosep consumables are packed in separate, sterilised packaging making them available via different ordering codes. By designing the device in this way, Advancis Surgical are able to increase health care professionals flexibility and help control surgical costs.

The Hemosep consumables are available as the following:
  • Hemosep Adult Concentrator kit
  • Intraoperative Suction Wand and Tubing
  • Intraoperative Kit consisting of: Wand, Spare Wand, Tubing, Blood Collection Reservoir.
  • Optional 1-to-3 Connector

Cost Benefits

Hemosep can introduce significant cost savings to the clinical teams that use it by reducing the need to add platelets to a patient and therefore also reducing the risk of postoperative bleeding.

Cost benefits

Cost of Platelets

Currently in the UK, a bag of platelets costs an average of £208. Hemosep’s unique method does not remove the platelets from the patient’s blood. By salvaging these cells and not disposing of them as with conventional cell savers, Hemosep saves the additional cost of using allogenic platelets.

 

Cost of Blood

Currently in the UK, the total cost of blood and components per unit rises by on average 4% year on year. 
 
Over 30,000 heart bypass operations are carried out in the UK every year with just over half needing blood. If Hemosep technology was applied to these heart bypasses alone, the savings made by the NHS would be considerable, giving the NHS greater flexibility in blood spending allocation.
Blood Cells

Clinical data

Novel Ultrafiltration Technique for Blood Conservation in Cardiac Operations

Clinical data
Authors

Terence Gourlay1, Serdar Gunaydin2

 
Objective
Following termination of cardiopulmonary bypass (CPB), the circuit contains a significant volume of diluted blood and various methods have been used to salvage this blood including direct transfusion or centrifugation/washing of the circuit volume. We designed a prospective clinical trial to determine the clinical outcomes of transfusion of autologous blood processed by a novel ultrafiltration device (Hemosep (Brightwake Ltd, Nottingham, UK)) in high risk patients undergoing coronary re-vascularisation.
Patients & Methods
Over a 6-month period, 40 high risk patients (Euroscore 6+) undergoing CABG with full heparin dose strategy were prospectively randomised into 2 equal groups (N=20). In Group 1, following the cessation of CPB, salvaged blood in the venous reservoir was pumped into the Hemosep bag until the desired volume has been introduced and processed for re-transfusion back to the patients. Group 2 patients were controls and this technology was not employed. Blood samples were collected at baseline (T1); at the end of the CPB (T2) and 24 h (T3), postoperatively.
Results
Mean processed blood was 775±125mL.80% (N=16) patients in Group 1 and 30% (N=6) in control group did not receive any bank blood (p<0.05). Postoperative bleeding was 545±180 cc in Group 1 versus 725±200 cc in control (p<0.05). IL-6 levels (pg/ml) were significantly lower in Group 1 versus control at T3 (11±4 versus 32±8; p<0.05). CD11b/CD18 levels (%) were significantly lower in Group 1 (14±4) versus control (23±8) at T3 (p<0.05).

1Bioenginering Unit, University of Strathclyde, UK; 2University of Kirkkale, Turkey

Social benefits

Offers a choice for patients with regard to their cultural and religious beliefs, when making
  • Offers a choice for patients with regard to their cultural and religious beliefs when making decisions over receiving blood and blood products during surgery
  • Provides the opportunity to receive the patient’s own red cells back, as well as all cell species
Social benefits